NTRA ▼ -0.3% - Natera, Inc.
$NTRA - Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
05-OCT-2026 08:04 AM ET
Share this post
More filings for $NTRA
NTRA ▼ -2.8% - Natera, Inc.Oct 18, 2026NTRA ▲ +1.8% - Natera, Inc.Oct 15, 2026NTRA ▲ +0.6% - Natera, Inc.Oct 9, 2026NTRA ▲ +0.6% - Natera, Inc.Oct 9, 2026NTRA ▼ -0.9% - Natera, Inc.Oct 7, 2026NTRA ▲ +1.0% - Natera, Inc.Oct 6, 2026
View full $NTRA filing history →💬 Comments
Loading comments…
Leave a comment